Payment overview · 2025
General Payments
$545.09
22 reported records · 8 companies
Healthcare provider profile · identity verified
Robert Brian Harris, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BERNICE, LA · NPI 1548219231
Verified facts
What the public records show
CMS Open Payments records show Robert Brian Harris, M.D. received $545.09 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 53.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 379 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $288.96 | 53.0% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.78 | 16.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 8.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.95 | 6.6% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $29.56 | 5.4% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $22.95 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.07 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.82 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $500.09 | 21 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $249.90 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $84.24 | 3 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $72.60 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $35.95 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $29.56 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
379 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 848 | 188 |
| Atorvastatin Calcium | Atorvastatin Calcium | 690 | 165 |
| Valsartan | Valsartan | 543 | 128 |
| Omeprazole | Omeprazole | 492 | 111 |
| Gabapentin | Gabapentin | 476 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 90 |
| Mounjaro | Tirzepatide | 379 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 362 | 74 |
| Losartan Potassium | Losartan Potassium | 301 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 59 |
| Lisinopril | Lisinopril | 268 | 64 |
| Metformin Hcl | Metformin Hcl | 253 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 59 |
| Carvedilol | Carvedilol | 193 | 54 |
| Potassium Chloride | Potassium Chloride | 184 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 43 |
| Jardiance | Empagliflozin | 164 | 41 |
| Tramadol Hcl | Tramadol Hcl | 160 | 78 |
| Enalapril Maleate | Enalapril Maleate | 152 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 35 |
| Alendronate Sodium | Alendronate Sodium | 140 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 55 |
| Furosemide | Furosemide | 128 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 28 |
| Trazodone Hcl | Trazodone Hcl | 124 | 29 |
| Meloxicam | Meloxicam | 119 | 42 |
| Simvastatin | Simvastatin | 111 | 31 |
| Eliquis | Apixaban | 107 | 25 |
| Allopurinol | Allopurinol | 98 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 29 |
| Prednisone | Prednisone | 97 | 80 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 29 |
| Pregabalin | Pregabalin | 91 | 21 |
| Nifedipine Er | Nifedipine | 90 | 19 |
| Atenolol | Atenolol | 89 | 22 |
| Trulicity | Dulaglutide | 86 | 18 |
| Sertraline Hcl | Sertraline Hcl | 85 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 70 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 79 | 66 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 17 |
| Famotidine | Famotidine | 73 | 22 |
| Montelukast Sodium | Montelukast Sodium | 69 | 13 |
| Spironolactone | Spironolactone | 67 | 18 |
| Celecoxib | Celecoxib | 66 | 21 |
| Ezetimibe | Ezetimibe | 62 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 61 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 13 |
| Np Thyroid | Thyroid,pork | 56 | suppressed |
| Finasteride | Finasteride | 55 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 34 |
| Memantine Hcl | Memantine Hcl | 55 | 13 |
| Glimepiride | Glimepiride | 54 | 14 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 53 | 48 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Ozempic | Semaglutide | 51 | 11 |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Nystatin | Nystatin | 47 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 36 |
| Tradjenta | Linagliptin | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 14 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 29 |
| Buspirone Hcl | Buspirone Hcl | 31 | 12 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 13 |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Colchicine | Colchicine | 24 | 14 |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 22 |
| Febuxostat | Febuxostat | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Ofloxacin | Ofloxacin | 22 | 19 |
| Alprazolam | Alprazolam | 21 | suppressed |
| Humalog | Insulin Lispro | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Veozah | Fezolinetant | 13 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $545.09 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AVYCAZ, Auvelity, BREZTRI, DALVANCE, EMBLAVEO, NURTEC ODT, OTEZLA, Omnipod, REPATHA, TEFLARO, UBRELVY, VRAYLAR, ZAVZPRET, bio-ConneKt | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error